コンテンツへスキップ
Merck
  • A protocol for efficient CRISPR-Cas9-mediated knock-in in colorectal cancer patient-derived organoids.

A protocol for efficient CRISPR-Cas9-mediated knock-in in colorectal cancer patient-derived organoids.

STAR protocols (2021-09-30)
Takuya Okamoto, Yasuko Natsume, Hitomi Yamanaka, Mayuko Fukuda, Ryoji Yao
要旨

Patient-derived organoids (PDOs) recapitulate the cellular heterogeneity of the original colorectal tumor tissue. Here, we describe a protocol to generate genetically modified PDOs to investigate cancer stem cells. This protocol uses the CRISPR-Cas9 system to knock-in the IRES-EGFP-P2A-iCaspase9 cassette into the 3' UTR of the potential cancer stem cell marker gene, which allows us to investigate their potential for self-replication and pluripotency. We describe the procedure for generating mutant PDOs and their application for stem cell research. For complete details on the generation and use of this protocol, please refer to Okamoto et al. Okamoto et al. (2021).

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
N-アセチル-L-システイン, BioReagent, suitable for cell culture
Sigma-Aldrich
Y-27632 二塩酸塩 一水和物, ≥98% (HPLC)
Sigma-Aldrich
ピューロマイシン 二塩酸塩, Ready Made Solution, from Streptomyces alboniger, 10 mg/mL in H2O, suitable for cell culture
Sigma-Aldrich
[ロイシン15]-ガストリンI、ヒト, ≥95% (HPLC)
Sigma-Aldrich
ネオマイシン 三硫酸塩 水和物, powder
Roche
PCR DIGプローブ合成キット, sufficient for 25 reaction (50 μL final reaction volume)
Roche
DIG発光検出キット, sufficient for 50 blots (10 cm x 10 cm each), kit of 1 (5 components), suitable for hybridization